IDEXX Laboratories Announces Second Quarter Results
- Record 10% revenue growth driven by CAG Diagnostics recurring revenue growth of 11%
- Record global premium instrument placements supporting 11% annual installed base growth
- EPS of $2.67, representing 71% growth
- 2023 revenue guidance updated to $3,660 million - $3,715 million
- 2023 EPS outlook increased to $9.64 - $9.90, a year-over-year increase of 20% - 23%
- None.
-
Records second quarter revenue growth of
10% reported and10% organic, driven by CAG Diagnostics recurring revenue growth of11% reported and12% organic
-
Achieves record second quarter global premium instrument placements, supporting
11% annual installed base growth
-
Delivers EPS of
, representing$2.67 71% growth as reported and77% on a comparable basis, including54% of EPS growth rate benefit from lapping of discrete R&D investments in the second quarter of 2022
-
Updates 2023 revenue guidance to
-$3,660 million , reflecting$3,715 million 8.5% -10% growth as reported and organically, driven by projected CAG Diagnostics recurring revenue growth of10% -11% as reported and organically
-
Increases 2023 EPS outlook to
-$9.64 , a year-over-year increase of$9.90 20% -23% as reported and24% -27% on a comparable basis, including ~12% combined EPS growth benefit from a customer contract resolution payment in Q1 2023 and lapping of discrete 2022 R&D investments
Second Quarter Results
The Company reports revenues of
Second quarter earnings per diluted share (“EPS”) were
"Strong execution by IDEXX commercial and operational teams drove excellent growth results and financial performance in the second quarter," said Jay Mazelsky, President and Chief Executive Officer. "Our customers' increasing embrace of IDEXX innovations, including cloud-based software services, helps them address the growing global demand for pet healthcare by improving efficiency while maintaining quality of care and supporting veterinary teams. We are proud of our progress in advancing our business strategy, aligned with our purpose to create long-term value for our customers, employees, and shareholders by enhancing the health and well-being of pets, people, and livestock."
Second Quarter Performance Highlights
Companion Animal Group
The Companion Animal Group generated revenue growth of
Additional
Strong global growth was achieved across IDEXX's testing modalities.
-
IDEXX VetLab® consumables generated
14% reported and15% organic revenue growth, with strong gains acrossU.S. and international regions supported by benefits from higher net price realization and an expanded global premium instrument installed base.
-
Reference laboratory diagnostic and consulting services generated
9% reported and organic revenue growth, driven by strong gains in theU.S. and moderate overall growth in international regions. International growth was constrained by pressure on same-store clinical visit levels, reflecting ongoing macro-economic impacts.
-
Rapid assay products revenues grew
11% as reported and12% organically, driven by strong growth in theU.S. , reflecting solid volume gains and benefits from higher net price realization.
Veterinary software, services and diagnostic imaging systems revenues grew
Water
Water revenues grew
Livestock, Poultry and Dairy (“LPD”)
LPD revenues were flat on a reported basis and grew
Gross Profit and Operating Profit
Gross profits increased
Operating margin was
2023 Growth and Financial Performance Outlook
The Company is updating its full year revenue growth outlook range to
The Company refined its full year reported operating margin outlook to
The Company's higher EPS outlook range of
The following table provides the Company's updated outlook for annual key financial metrics in 2023:
Amounts in millions except per share data and percentages
Growth and Financial Performance Outlook |
|
2023 |
||
|
|
|
|
|
Revenue |
|
|
- |
|
Reported growth |
|
|
- |
|
Organic growth |
|
|
- |
|
CAG Diagnostics Recurring Revenue Growth |
|
|
|
|
Reported growth |
|
|
- |
|
Organic growth |
|
|
- |
|
Operating Margin |
|
|
- |
|
Operating margin expansion |
|
270 bps |
- |
300 bps |
Negative impact of foreign exchange |
|
~ 60 bps |
||
Comparable margin expansion |
|
330 bps |
- |
360 bps |
Positive impact of discrete in-license of technology and customer contract resolution |
|
~ 280 bps |
||
EPS |
|
|
- |
|
Reported growth |
|
|
- |
|
Comparable growth |
|
|
- |
|
Positive impact of discrete in-license of technology and customer contract resolution |
|
|
||
Other Key Metrics |
|
|
|
|
Net interest expense |
|
~ |
||
Share-based compensation tax benefit |
|
~ |
||
Share-based compensation tax rate benefit |
|
~ |
||
Effective tax rate |
|
|
- |
|
Share-based compensation EPS impact |
|
~ |
||
Reduction in average shares outstanding |
|
0.5 % |
- |
|
Operating Cash Flow |
|
|
||
Free Cash Flow |
|
|
||
Capital Expenditures |
|
~ |
||
The following table outlines estimates of foreign currency exchange rate impacts, net of foreign currency hedging transactions, and foreign currency exchange rate assumptions reflected in the above financial performance outlook for 2023.
Estimated Foreign Currency Exchange Rate Impacts |
|
2023 |
||
|
|
|
|
|
Revenue growth rate impact |
|
~ 20 bps |
||
CAG Diagnostics recurring revenue growth rate impact |
|
~ 20 bps |
||
Operating margin growth impact |
|
(~ 60 bps) |
||
EPS impact |
|
(~ |
||
EPS growth impact |
|
(~ |
||
|
|
|
|
|
Go-Forward Foreign Currency Exchange Rate Assumptions |
|
2023 |
||
In |
|
|
|
|
euro |
|
|
||
British pound |
|
|
||
Canadian dollar |
|
|
||
Australian dollar |
|
|
||
Relative to the |
|
|
|
|
Japanese yen |
|
|
||
Chinese renminbi |
|
|
||
Brazilian real |
|
|
||
Conference Call and Webcast Information
IDEXX Laboratories, Inc. will be hosting a conference call today at 8:30 a.m. (EDT) to discuss its second quarter 2023 results and management’s outlook. To participate in the conference call, dial 1-877-612-6725 or 1-773-305-6837 and reference passcode 351415. Individuals can access a live webcast of the conference call through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. (EDT) on that day via the same link and will remain available for one year.
2023 Investor Day
IDEXX Laboratories, Inc. will host its 2023 Investor Day on Thursday, August 10, 2023 from 8:00 am to approximately 12:00 pm (EDT). A live audio webcast and accompanying slide presentations will be available at www.idexx.com/investors. An archived webcast replay of the event will be available approximately one hour following the event at www.idexx.com/investors. For additional information contact investorrelations@idexx.com.
About IDEXX Laboratories, Inc.
IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500® Index. Headquartered in
Note Regarding Forward-Looking Statements
This earnings release contains statements about the Company’s business prospects and estimates of the Company’s financial results for future periods that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are included above under "2023 Growth and Financial Performance Outlook" and elsewhere and can be identified by the use of words such as "expects", "may", "anticipates", "intends", "would", "will", "plans", "believes", "estimates", "projected", "should", and similar words and expressions. Our forward-looking statements include statements relating to our expectations regarding financial performance; revenue growth and EPS outlooks; operating and free cash flow forecast; projected impact of foreign currency exchange rates and interest rates; projected operating margins and expenses and capital expenditures; projected tax, tax rate and EPS benefits from share-based compensation arrangements; and projected effective tax rates, reduction of average shares outstanding and net interest expense. These statements are intended to provide management's expectation of future events as of the date of this earnings release; are based on management's estimates, projections, beliefs and assumptions as of the date of this earnings release; and are not guarantees of future performance. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among other things, the matters described under the headings "Business," "Risk Factors," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About Market Risk" in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 and in the corresponding sections of the Company's Quarterly Reports on Form 10-Q for the quarters ended March 31, 2023 and June 30, 2023, as well as those described from time to time in the Company’s other filings with the
Statement Regarding Non-GAAP Financial Measures
The following defines terms and conventions and provides reconciliations regarding certain measures used in this earnings release and/or the accompanying earnings conference call that are not required by, or presented in accordance with, generally accepted accounting principles in
Constant currency - Constant currency references are non-GAAP financial measures which exclude the impact of changes in foreign currency exchange rates and are consistent with how management evaluates our performance and comparisons with prior and future periods. We estimated the net impacts of currency on our revenue, gross profit, operating profit, and EPS results by restating results to the average exchange rates or exchange rate assumptions for the comparative period, which includes adjusting for the estimated impacts of foreign currency hedging transactions and certain impacts on our effective tax rates. These estimated currency changes impacted second quarter 2023 results as follows: decreased gross profit growth by
Growth and organic revenue growth - All references to growth and organic growth refer to growth compared to the equivalent prior year period unless specifically noted. Organic revenue growth is a non-GAAP financial measure that represents the percent change in revenue, as compared to the same period for the prior year, net of the impact of changes in foreign currency exchange rates, certain business acquisitions, and divestitures. Management believes that reporting organic revenue growth provides useful information to investors by facilitating easier comparisons of our revenue performance with prior and future periods and to the performance of our peers. Organic revenue growth should be considered in addition to, and not as a replacement of or a superior measure to, revenue growth reported in accordance with GAAP. See the supplementary analysis of results below for a reconciliation of reported revenue growth to organic revenue growth for the three months and six months ended June 30, 2023. Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts. Please refer to the 2023 Growth and Financial Performance Outlook section of this earnings release for estimated full year 2023 organic revenue growth for the Company and CAG Diagnostics recurring revenue growth. The percentage change in revenue resulting from acquisitions represents revenues during the current year period, limited to the initial 12 months from the date of the acquisition, that are directly attributable to business acquisitions. Revenue from acquisitions is not expected to have an impact on projected full year 2023 revenue growth or CAG Diagnostics recurring revenue growth.
Comparable growth metrics - Comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) are non-GAAP financial measures and exclude the impact of changes in foreign currency exchange rates and non-recurring or unusual items (if any). Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts. Management believes that reporting comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) provides useful information to investors because it enables better period-over-period comparisons of the fundamental financial results by excluding items that vary independent of performance and provides greater transparency to investors regarding key metrics used by management. Comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) should be considered in addition to, and not as replacements of or superior measures to, gross profit growth, gross margin gain, operating expense growth, operating profit growth and operating margin gain reported in accordance with GAAP.
The reconciliation of these non-GAAP financial measures is as follows:
|
|
Three Months Ended |
Year-over-Year |
|
Six Months Ended |
Year-over-Year |
||||||||||||
|
|
June 30, |
|
June 30, |
Change |
|
June 30, |
|
June 30, |
Change |
||||||||
Dollar amounts in thousands |
|
|
2023 |
|
|
|
2022 |
|
|
|
|
2023 |
|
|
|
2022 |
|
|
Gross Profit (as reported) |
|
$ |
572,850 |
|
|
$ |
514,032 |
|
|
|
$ |
1,115,821 |
|
|
$ |
1,012,785 |
|
|
Gross margin |
|
|
60.7 |
% |
|
|
59.7 |
% |
100 bps |
|
|
60.5 |
% |
|
|
59.7 |
% |
80 bps |
Less: comparability adjustments |
|
|
|
|
|
|
|
|
|
|
||||||||
Change from currency |
|
|
(8,676 |
) |
|
|
— |
|
|
|
|
(24,502 |
) |
|
|
— |
|
|
Comparable gross profit growth |
|
$ |
581,526 |
|
|
$ |
514,032 |
|
|
|
$ |
1,140,323 |
|
|
$ |
1,012,785 |
|
|
Comparable gross margin and gross margin gain (or growth) |
|
|
61.4 |
% |
|
|
59.7 |
% |
160 bps |
|
|
61.1 |
% |
|
|
59.7 |
% |
140 bps |
|
|
|
|
|
|
|
|
|
|
|
||||||||
Operating expenses (as reported) |
|
$ |
276,706 |
|
|
$ |
334,966 |
|
(17)% |
|
$ |
539,278 |
|
|
$ |
585,375 |
|
(8)% |
Less: comparability adjustments |
|
|
|
|
|
|
|
|
|
|
||||||||
Change from currency |
|
|
(623 |
) |
|
|
— |
|
|
|
|
(4,805 |
) |
|
|
— |
|
|
Comparable operating expense growth |
|
$ |
277,329 |
|
|
$ |
334,966 |
|
(17)% |
|
$ |
544,083 |
|
|
$ |
585,375 |
|
(7)% |
|
|
|
|
|
|
|
|
|
|
|
||||||||
Income from operations (as reported) |
|
$ |
296,144 |
|
|
$ |
179,066 |
|
|
|
$ |
576,543 |
|
|
$ |
427,410 |
|
|
Operating margin |
|
|
31.4 |
% |
|
|
20.8 |
% |
1,060 bps |
|
|
31.3 |
% |
|
|
25.2 |
% |
610 bps |
Less: comparability adjustments |
|
|
|
|
|
|
|
|
|
|
||||||||
Change from currency |
|
|
(8,054 |
) |
|
|
— |
|
|
|
|
(19,698 |
) |
|
|
— |
|
|
Comparable operating profit growth |
|
$ |
304,198 |
|
|
$ |
179,066 |
|
|
|
$ |
596,241 |
|
|
$ |
427,410 |
|
|
Comparable operating margin and operating margin gain (or growth) |
|
|
32.1 |
% |
|
|
20.8 |
% |
1,130 bps |
|
|
31.9 |
% |
|
|
25.2 |
% |
680 bps |
Amounts presented may not recalculate due to rounding. |
||||||||||||||||||
Projected 2023 comparable operating margin expansion outlined in the 2023 Growth and Financial Performance Outlook section of this earnings release reflects projected full year 2023 reported operating margin adjusted for estimated positive year-over-year foreign currency exchange rate change impact of approximately 60 basis points.
These impacts described above reconcile reported gross profit growth, gross margin gain, operating expense growth, operating profit growth and operating margin gain (including projected 2023 operating margin expansion) to comparable gross profit growth, comparable gross margin gain, comparable operating expense growth, comparable operating profit growth and comparable operating margin gain for the Company.
Comparable EPS growth - Comparable EPS growth is a non-GAAP financial measure that represents the percentage change in earnings per share (diluted) ("EPS") for a measurement period, as compared to the prior base period, net of the impact of changes in foreign currency exchange rates from the prior base period and excluding the tax benefits of share-based compensation activity under ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, and non-recurring or unusual items (if any). Management believes comparable EPS growth is a more useful way to measure the Company’s business performance than EPS growth because it enables better period-over-period comparisons of the fundamental financial results by excluding items that vary independent of performance and provides greater transparency to investors regarding a key metric used by management. Comparable EPS growth should be considered in addition to, and not as a replacement of or a superior measure to, EPS growth reported in accordance with GAAP. Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts.
The reconciliation of this non-GAAP financial measure is as follows:
|
|
Three Months Ended |
|
Year-over-Year |
|
Six Months Ended |
|
Year-over-Year |
||||||||
|
|
June 30, |
|
June 30, |
|
Growth |
|
June 30, |
|
June 30, |
|
Growth |
||||
|
|
2023 |
|
2022 |
|
|
|
2023 |
|
2022 |
|
|
||||
Earnings per share (diluted) |
|
$ |
2.67 |
|
$ |
1.56 |
|
|
|
$ |
5.22 |
|
$ |
3.82 |
|
|
Less: comparability adjustments |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Share-based compensation activity |
|
|
0.04 |
|
|
0.03 |
|
|
|
|
0.10 |
|
|
0.09 |
|
|
Change from currency |
|
|
(0.07) |
|
|
— |
|
|
|
|
(0.18) |
|
|
— |
|
|
Comparable EPS growth |
|
|
2.70 |
|
|
1.53 |
|
|
|
|
5.30 |
|
|
3.73 |
|
|
Amounts presented may not recalculate due to rounding. |
||||||||||||||||
Projected 2023 comparable EPS growth outlined in the 2023 Growth and Financial Performance Outlook section of this earnings release reflects adjustments including estimated positive share-based compensation activity of
These impacts and those described in the constant currency note above reconcile reported EPS growth (including projected 2023 reported EPS growth) to comparable EPS growth for the Company.
Free cash flow - Free cash flow is a non-GAAP financial measure and means, with respect to a measurement period, the cash generated from operations during that period, reduced by the Company’s investments in property and equipment. Management believes free cash flow is a useful measure because it indicates the cash the operations of the business are generating after appropriate reinvestment for recurring investments in property and equipment that are required to operate the business. Free cash flow should be considered in addition to, and not as a replacement of or a superior measure to, net cash provided by operating activities. See the supplementary analysis of results below for our calculation of free cash flow for the three and six months ended June 30, 2023 and 2022. To estimate projected 2023 free cash flow, we have deducted projected purchases of property and equipment (also referred to as capital expenditures) of approximately
Debt to Adjusted EBITDA (Leverage Ratios) - Adjusted EBITDA, gross debt, and net debt are non-GAAP financial measures. Adjusted EBITDA is a non-GAAP financial measure of earnings before interest, taxes, depreciation, amortization, non-recurring transaction expenses incurred in connection with acquisitions, share-based compensation expense, and certain other non-cash losses and charges. Management believes that reporting Adjusted EBITDA, gross debt and net debt in the Debt to Adjusted EBITDA ratios provides supplemental analysis to help investors further evaluate the Company's business performance and available borrowing capacity under the Company's credit facility. Adjusted EBITDA, gross debt, and net debt should be considered in addition to, and not as replacements of or superior measures to, net income or total debt reported in accordance with GAAP. For further information on how Adjusted EBITDA and the Debt to Adjusted EBITDA Ratios are calculated, see the Company's Annual Report on Form 10-K for the year ended December 31, 2022 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2023.
IDEXX Laboratories, Inc. and Subsidiaries |
|
|
|
|
|
|
|
|||
Condensed Consolidated Statement of Operations |
|
|
|
|
|
|
|
|||
Amounts in thousands except per share data (Unaudited) |
|
|
|
|
|
|
|
|||
|
|
|
|
Three Months Ended |
|
Six Months Ended |
||||
|
|
|
|
June 30, |
|
June 30, |
|
June 30, |
|
June 30, |
|
|
|
|
2023 |
|
2022 |
|
2023 |
|
2022 |
Revenue: |
|
Revenue |
|
|
|
|
|
|
|
|
Expenses and Income: |
|
Cost of revenue |
|
370,780 |
|
346,514 |
|
728,004 |
|
684,310 |
|
|
Gross profit |
|
572,850 |
|
514,032 |
|
1,115,821 |
|
1,012,785 |
|
|
Sales and marketing |
|
140,532 |
|
130,257 |
|
288,336 |
|
262,549 |
|
|
General and administrative |
|
89,669 |
|
81,488 |
|
159,770 |
|
159,437 |
|
|
Research and development |
|
46,505 |
|
123,221 |
|
91,172 |
|
163,389 |
|
|
Income from operations |
|
296,144 |
|
179,066 |
|
576,543 |
|
427,410 |
|
|
Interest expense, net |
|
(10,215) |
|
(7,983) |
|
(22,926) |
|
(14,836) |
|
|
Income before provision for income taxes |
|
285,929 |
|
171,083 |
|
553,617 |
|
412,574 |
|
|
Provision for income taxes |
|
61,693 |
|
39,104 |
|
115,327 |
|
86,630 |
Net Income: |
|
Net income attributable to stockholders |
|
|
|
|
|
|
|
|
|
|
Earnings per share: Basic |
|
|
|
|
|
|
|
|
|
|
Earnings per share: Diluted |
|
|
|
|
|
|
|
|
|
|
Shares outstanding: Basic |
|
83,086 |
|
83,922 |
|
83,039 |
|
84,164 |
|
|
Shares outstanding: Diluted |
|
83,983 |
|
84,858 |
|
83,980 |
|
85,222 |
IDEXX Laboratories, Inc. and Subsidiaries |
|
|
|
|
|
|
|
|||
Selected Operating Information (Unaudited) |
|
|
|
|
|
|
|
|||
|
|
|
|
Three Months Ended |
|
Six Months Ended |
||||
|
|
|
|
June 30, |
|
June 30, |
|
June 30, |
|
June 30, |
|
|
|
|
2023 |
|
2022 |
2023 |
|
2022 |
|
Operating Ratios |
|
Gross profit |
|
|
|
|
|
|
|
|
(as a percentage of revenue): |
|
Sales, marketing, general and administrative expense |
|
|
|
|
|
|
|
|
|
|
Research and development expense |
|
|
|
|
|
|
|
|
|
|
Income from operations1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1Amounts presented may not recalculate due to rounding. |
|
|
|
|
|
|
|
|||
IDEXX Laboratories, Inc. and Subsidiaries |
||||||||||
Segment Information |
||||||||||
Amounts in thousands (Unaudited) |
||||||||||
|
|
|
|
|
|
|
|
|
||
|
|
|
|
Three Months Ended |
||||||
|
|
|
|
June 30, 2023 |
|
Percent of
|
|
June 30, 2022 |
|
Percent of
|
|
|
|
|
|
|
|
||||
Revenue: |
|
CAG |
|
|
|
|
|
|
|
|
|
|
Water |
|
43,029 |
|
|
|
39,195 |
|
|
|
|
LPD |
|
29,911 |
|
|
|
29,889 |
|
|
|
|
Other |
|
4,038 |
|
|
|
7,375 |
|
|
|
|
Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross Profit: |
|
CAG |
|
|
|
|
|
|
|
|
|
|
Water |
|
30,319 |
|
|
|
27,359 |
|
|
|
|
LPD |
|
16,086 |
|
|
|
16,996 |
|
|
|
|
Other |
|
736 |
|
|
|
3,423 |
|
|
|
|
Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from Operations: |
|
CAG |
|
|
|
|
|
|
|
|
|
|
Water |
|
19,820 |
|
|
|
17,920 |
|
|
|
|
LPD |
|
1,951 |
|
|
|
3,230 |
|
|
|
|
Other |
|
(1,136) |
|
(28.1)% |
|
1,390 |
|
|
|
|
Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
Six Months Ended |
||||||
|
|
|
|
June 30, 2023 |
|
Percent of
|
|
June 30, 2022 |
|
Percent of
|
|
|
|
|
|
|
|
||||
Revenue: |
|
CAG |
|
|
|
|
|
|
|
|
|
|
Water |
|
81,912 |
|
|
|
75,566 |
|
|
|
|
LPD |
|
59,119 |
|
|
|
60,759 |
|
|
|
|
Other |
|
8,863 |
|
|
|
15,499 |
|
|
|
|
Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross Profit: |
|
CAG |
|
|
|
|
|
|
|
|
|
|
Water |
|
57,587 |
|
|
|
53,096 |
|
|
|
|
LPD |
|
31,139 |
|
|
|
36,543 |
|
|
|
|
Other |
|
2,629 |
|
|
|
7,793 |
|
|
|
|
Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from Operations: |
|
CAG |
|
|
|
|
|
|
|
|
|
|
Water |
|
36,791 |
|
|
|
34,574 |
|
|
|
|
LPD |
|
3,259 |
|
|
|
9,967 |
|
|
|
|
Other |
|
(766) |
|
(8.6)% |
|
3,218 |
|
|
|
|
Total |
|
|
|
|
|
|
|
|
IDEXX Laboratories, Inc. and Subsidiaries |
||||||||||||||
Revenues and Revenue Growth Analysis by Product and Service Categories and by Domestic and International Markets |
||||||||||||||
Amounts in thousands (Unaudited) |
||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
Three Months Ended |
|
|
|
|
|
|
|
|
|
|
||
|
|
June 30, 2023 |
|
June 30, 2022 |
|
Dollar
|
|
Reported
|
|
Percentage
|
|
Percentage
|
|
Organic
|
Net Revenue |
|
|
|
|
|
|
|
|||||||
CAG |
|
|
|
|
|
|
|
|
|
( |
|
— |
|
|
|
|
594,395 |
|
532,626 |
|
61,769 |
|
|
|
— |
|
— |
|
|
International |
|
272,257 |
|
251,461 |
|
20,796 |
|
|
|
( |
|
— |
|
|
Water |
|
43,029 |
|
39,195 |
|
3,834 |
|
|
|
( |
|
1.7 % |
|
|
|
|
21,208 |
|
19,533 |
|
1,675 |
|
|
|
— |
|
1.4 % |
|
|
International |
|
21,821 |
|
19,662 |
|
2,159 |
|
|
|
( |
|
2.1 % |
|
|
LPD |
|
29,911 |
|
29,889 |
|
22 |
|
|
|
( |
|
— |
|
|
|
|
4,422 |
|
3,742 |
|
680 |
|
|
|
— |
|
— |
|
|
International |
|
25,489 |
|
26,147 |
|
(658) |
|
( |
|
( |
|
— |
|
( |
Other |
|
4,038 |
|
7,375 |
|
(3,337) |
|
( |
|
— |
|
— |
|
( |
Total Company |
|
|
|
|
|
|
|
|
|
( |
|
|
|
|
|
|
621,607 |
|
559,825 |
|
61,782 |
|
|
|
— |
|
— |
|
|
International |
|
322,023 |
|
300,721 |
|
21,302 |
|
|
|
( |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
Three Months Ended |
|
|
|
|
|
|
|
|
|
|
||
|
|
June 30, 2023 |
|
June 30, 2022 |
|
Dollar
|
|
Reported
|
|
Percentage
|
|
Percentage
|
|
Organic
|
Net CAG Revenue |
|
|
|
|
|
|
|
|||||||
CAG Diagnostics recurring revenue: |
|
|
|
|
|
|
|
|
|
( |
|
— |
|
|
IDEXX VetLab consumables |
|
303,735 |
|
266,079 |
|
37,656 |
|
|
|
( |
|
— |
|
|
Rapid assay products |
|
97,340 |
|
87,481 |
|
9,859 |
|
|
|
( |
|
— |
|
|
Reference laboratory diagnostic and consulting services |
|
330,106 |
|
304,130 |
|
25,976 |
|
|
|
( |
|
— |
|
|
CAG Diagnostics services and accessories |
|
31,295 |
|
27,723 |
|
3,572 |
|
|
|
( |
|
— |
|
|
CAG Diagnostics capital – instruments |
|
34,054 |
|
36,227 |
|
(2,173) |
|
( |
|
( |
|
— |
|
( |
Veterinary software, services and diagnostic imaging systems |
|
70,122 |
|
62,447 |
|
7,675 |
|
|
|
( |
|
— |
|
|
Net CAG revenue |
|
|
|
|
|
|
|
|
|
( |
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
|
|
|
|
|
|
|
|||
|
|
June 30, 2023 |
|
June 30, 2022 |
|
Dollar
|
|
Reported
|
|
Percentage
|
|
Percentage
|
|
Organic
|
|
|
|
|
|
|
|
|
|
||||||||
CAG Diagnostics recurring revenue: |
|
|
|
|
|
|
|
|
|
( |
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
— |
|
|
|
International |
|
|
|
|
|
|
|
|
|
( |
|
— |
|
|
|
1See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding. |
|||||||||||||||
IDEXX Laboratories, Inc. and Subsidiaries |
||||||||||||||
Revenues and Revenue Growth Analysis by Product and Service Categories and by Domestic and International Markets |
||||||||||||||
Amounts in thousands (Unaudited) |
||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
Six Months Ended |
|
|
|
|
|
|
|
|
|
|
||
|
|
June 30, 2023 |
|
June 30, 2022 |
|
Dollar
|
|
Reported
|
|
Percentage
|
|
Percentage
|
|
Organic
|
Net Revenue |
|
|
|
|
|
|
|
|||||||
CAG |
|
|
|
|
|
|
|
|
|
( |
|
— |
|
|
|
|
1,158,922 |
|
1,032,392 |
|
126,530 |
|
|
|
— |
|
— |
|
|
International |
|
535,009 |
|
512,879 |
|
22,130 |
|
|
|
( |
|
— |
|
|
Water |
|
81,912 |
|
75,566 |
|
6,346 |
|
|
|
( |
|
|
|
|
|
|
41,128 |
|
37,364 |
|
3,764 |
|
|
|
— |
|
|
|
|
International |
|
40,784 |
|
38,202 |
|
2,582 |
|
|
|
( |
|
|
|
|
LPD |
|
59,119 |
|
60,759 |
|
(1,640) |
|
( |
|
( |
|
— |
|
( |
|
|
8,965 |
|
7,602 |
|
1,363 |
|
|
|
— |
|
— |
|
|
International |
|
50,154 |
|
53,157 |
|
(3,003) |
|
( |
|
( |
|
— |
|
( |
Other |
|
8,863 |
|
15,499 |
|
(6,636) |
|
( |
|
( |
|
— |
|
( |
Total Company |
|
|
|
|
|
|
|
|
|
( |
|
|
|
|
|
|
1,212,020 |
|
1,085,731 |
|
126,289 |
|
|
|
— |
|
— |
|
|
International |
|
631,805 |
|
611,364 |
|
20,441 |
|
|
|
( |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
Six Months Ended |
|
|
|
|
|
|
|
|
|
|
||
|
|
June 30, 2023 |
|
June 30, 2022 |
|
Dollar
|
|
Reported
|
|
Percentage
|
|
Percentage
|
|
Organic
|
Net CAG Revenue |
|
|
|
|
|
|
|
|||||||
CAG Diagnostics recurring revenue: |
|
|
|
|
|
|
|
|
|
( |
|
— |
|
|
IDEXX VetLab consumables |
|
594,849 |
|
533,252 |
|
61,597 |
|
|
|
( |
|
— |
|
|
Rapid assay products |
|
179,372 |
|
162,000 |
|
17,372 |
|
|
|
( |
|
— |
|
|
Reference laboratory diagnostic and consulting services |
|
653,286 |
|
599,205 |
|
54,081 |
|
|
|
( |
|
— |
|
|
CAG Diagnostics services and accessories |
|
61,871 |
|
55,766 |
|
6,105 |
|
|
|
( |
|
— |
|
|
CAG Diagnostics capital – instruments |
|
67,198 |
|
73,224 |
|
(6,026) |
|
( |
|
( |
|
— |
|
( |
Veterinary software, services and diagnostic imaging systems |
|
137,355 |
|
121,824 |
|
15,531 |
|
|
|
( |
|
— |
|
|
Net CAG revenue |
|
|
|
|
|
|
|
|
|
( |
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
Six Months Ended |
|
|
|
|
|
|
|
|
|
|
|||
|
|
June 30, 2023 |
|
June 30, 2022 |
|
Dollar
|
|
Reported
|
|
Percentage
|
|
Percentage
|
|
Organic
|
|
|
|
|
|
|
|
|
|
||||||||
CAG Diagnostics recurring revenue: |
|
|
|
|
|
|
|
|
|
( |
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
— |
|
— |
|
|
|
International |
|
|
|
|
|
|
|
|
|
( |
|
— |
|
|
|
1See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding. |
|||||||||||||||
IDEXX Laboratories, Inc. and Subsidiaries |
||||||
Condensed Consolidated Balance Sheet |
||||||
Amounts in thousands (Unaudited) |
||||||
|
|
|
|
June 30, 2023 |
|
December 31,
|
|
|
|
|
|
||
Assets: |
|
Current Assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
|
|
|
|
|
Accounts receivable, net |
|
461,858 |
|
400,619 |
|
|
Inventories |
|
395,141 |
|
367,823 |
|
|
Other current assets |
|
189,188 |
|
220,489 |
|
|
Total current assets |
|
1,179,025 |
|
1,101,477 |
|
|
Property and equipment, net |
|
683,270 |
|
649,474 |
|
|
Other long-term assets, net |
|
1,008,511 |
|
995,814 |
|
|
Total assets |
|
|
|
|
Liabilities and Stockholders' |
|
|
|
|
|
|
Equity: |
|
Current Liabilities: |
|
|
|
|
|
|
Accounts payable |
|
|
|
|
|
|
Accrued liabilities |
|
399,425 |
|
433,662 |
|
|
Line of credit |
|
264,000 |
|
579,000 |
|
|
Current portion of long-term debt |
|
74,991 |
|
74,982 |
|
|
Deferred revenue |
|
37,779 |
|
37,938 |
|
|
Total current liabilities |
|
883,859 |
|
1,235,803 |
|
|
Long-term debt, net of current portion |
|
696,844 |
|
694,387 |
|
|
Other long-term liabilities, net |
|
196,242 |
|
207,838 |
|
|
Total long-term liabilities |
|
893,086 |
|
902,225 |
|
|
Total stockholders' equity |
|
1,093,861 |
|
608,737 |
|
|
Total liabilities and stockholders' equity |
|
|
|
|
IDEXX Laboratories, Inc. and Subsidiaries |
||||||||||||
Selected Balance Sheet Information (Unaudited) |
||||||||||||
|
|
|
|
June 30,
|
|
March 31,
|
|
December 31,
|
|
September 30,
|
|
June 30,
|
Selected Balance Sheet Information: |
|
Days sales outstanding1 |
|
43.9 |
|
42.9 |
|
43.4 |
|
43.4 |
|
43.2 |
|
|
Inventory turns2 |
|
1.3 |
|
1.3 |
|
1.3 |
|
1.3 |
|
1.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
1Days sales outstanding represents the average of the accounts receivable balances at the beginning and end of each quarter divided by revenue for that quarter, the result of which is then multiplied by 91.25 days. |
||||||||||||
2Inventory turns represent inventory-related cost of product revenue for the twelve months preceding each quarter-end divided by the average inventory balances at the beginning and end of each quarter. |
||||||||||||
IDEXX Laboratories, Inc. and Subsidiaries |
||||||
Condensed Consolidated Statement of Cash Flows |
||||||
Amounts in thousands (Unaudited) |
||||||
|
|
|
|
Six Months Ended |
||
|
|
|
|
June 30, 2023 |
|
June 30, 2022 |
|
|
|
|
|
||
Operating: |
|
Cash Flows from Operating Activities: |
|
|
|
|
|
|
Net income |
|
|
|
|
|
|
Non-cash adjustments to net income |
|
76,246 |
|
61,563 |
|
|
Changes in assets and liabilities |
|
(130,310) |
|
(206,951) |
|
|
Net cash provided by operating activities |
|
384,226 |
|
180,556 |
Investing: |
|
Cash Flows from Investing Activities: |
|
|
|
|
|
|
Purchases of property and equipment |
|
(66,981) |
|
(61,924) |
|
|
Equity investment |
|
— |
|
(25,000) |
|
|
Acquisition of intangible assets |
|
— |
|
(10,000) |
|
|
Net cash used by investing activities |
|
(66,981) |
|
(96,924) |
Financing: |
|
Cash Flows from Financing Activities: |
|
|
|
|
|
|
(Repayments) borrowings under credit facility, net |
|
(315,000) |
|
537,500 |
|
|
Payment of senior debt |
|
— |
|
(75,000) |
|
|
Proceeds from maturity of net investment hedges |
|
6,256 |
|
— |
|
|
Payments for the acquisition-related contingent consideration and holdbacks |
|
(1,780) |
|
(2,816) |
|
|
Repurchases of common stock |
|
— |
|
(573,060) |
|
|
Proceeds from exercises of stock options and employee stock purchase plans |
|
23,086 |
|
18,379 |
|
|
Shares withheld for statutory tax withholding payments on restricted stock |
|
(9,676) |
|
(10,390) |
|
|
Net cash used by financing activities |
|
(297,114) |
|
(105,387) |
|
|
Net effect of changes in exchange rates on cash |
|
161 |
|
(8,337) |
|
|
Net increase (decrease) in cash and cash equivalents |
|
20,292 |
|
(30,092) |
|
|
Cash and cash equivalents, beginning of period |
|
112,546 |
|
144,454 |
|
|
Cash and cash equivalents, end of period |
|
|
|
|
IDEXX Laboratories, Inc. and Subsidiaries |
||||||||||
Free Cash Flow |
||||||||||
Amounts in thousands except per share data (Unaudited) |
||||||||||
|
|
|
|
Three Months Ended |
|
Six Months Ended |
||||
|
|
|
|
June 30, 2023 |
|
June 30, 2022 |
|
June 30, 2023 |
|
June 30, 2022 |
|
|
|
|
|
|
|
||||
Free Cash Flow: |
|
Net cash provided by operating activities |
|
|
|
|
|
|
|
|
|
|
Investing cash flows attributable to purchases of property and equipment |
|
(27,470) |
|
(30,086) |
|
(66,981) |
|
(61,924) |
|
|
Free cash flow1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1See Statements Regarding Non-GAAP Financial Measures, above. |
||||||||||
IDEXX Laboratories, Inc. and Subsidiaries |
|
|
|
|
|
|
|
|
Common Stock Repurchases |
|
|
|
|
|
|
|
|
Amounts in thousands except per share data (Unaudited) |
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Six Months Ended |
||||
|
|
June 30, 2023 |
|
June 30, 2022 |
|
June 30, 2023 |
|
June 30, 2022 |
|
|
|
|
|
||||
Shares repurchased in the open market |
|
— |
|
809 |
|
— |
|
1,311 |
Shares acquired through employee surrender for statutory tax withholding |
|
— |
|
— |
|
19 |
|
21 |
Total shares repurchased |
|
— |
|
809 |
|
19 |
|
1,332 |
|
|
|
|
|
|
|
|
|
Cost of shares repurchased in the open market |
|
$ — |
|
|
|
$ — |
|
|
Cost of shares for employee surrenders |
|
|
|
|
|
|
|
|
Total cost of shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Average cost per share – open market repurchases |
|
$ — |
|
|
|
$ — |
|
|
Average cost per share – employee surrenders |
|
|
|
|
|
|
|
|
Average cost per share – total |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20230731815693/en/
John Ravis, Investor Relations, 1-207-556-8155
Source: IDEXX Laboratories, Inc.
FAQ
What were IDEXX Laboratories, Inc.'s second quarter 2023 revenues?
What drove the revenue growth in the second quarter?
What was the EPS in the second quarter?
What is the updated 2023 revenue guidance?